India Proposed Amendment to New Drugs and Clinical Trials Rules

India Proposed Amendment To New Drugs And Clinical Trials Rules

The India Ministry of Health and Family Welfare (MoHFW) proposed an amendment to New Drugs and Clinical Trials (Third Amendment) Rules, 2022 regarding new drugs, new APIs, clinical trials, and bioavailability/bioequivalence studies registration forms relating to Central Licensing Authority.

This amendment shows the following forms and their respective instructions:

Sorry, this premium content is for RegASK clients only.

Want to access the whole content of the alert or browse all the news? 

Have a
regulatory affairs

Regulatory Affair Icon